In Europe, three CD19-targeted CAR T products have been approved for the treatment of lymphoid malignancies: tisagenlecleucel (tisa-cel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL), axicabtagene ciloleucel (axi-cel) for the treatment of DLBCL and primary mediastinal B-cell lymphoma (PMBCL), and brexucabtagene autoleucel for the treatment of mantle cell lymphoma (MCL) and B-ALL. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.